M
Manas AI
AI-powered drug discovery accelerating treatments for cancer and rare diseases
About Manas AI
Manas AI focuses on revolutionizing drug discovery, particularly in oncology, by leveraging AI and computational power to develop treatments for aggressive cancers like triple negative breast cancer, prostate cancer, and lymphoma. The company operates in the pharmaceutical and biotechnology market, targeting both cancer and rare diseases. Utilizing proprietary AI models, generative computational chemistry, and advanced biology, Manas AI aims to significantly reduce drug development timelines and costs. The business model involves creating bespoke chemical libraries and employing AI filters to identify high-potential therapeutic candidates with unprecedented speed and accuracy. Manas AI's partnership with Microsoft enhances its capabilities by integrating world-class AI infrastructure, enabling molecular docking speeds 100 times faster than traditional systems. The company serves pharmaceutical companies and research institutions seeking efficient and cost-effective drug development solutions. Keywords: oncology, AI, drug discovery, cancer treatment, computational chemistry, molecular docking, pharmaceutical, biotechnology, therapeutic candidates, Microsoft partnership.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- San Francisco, United States
- Employees
- 28
- Open positions
- None listed
- Dealroom signal
- 95.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Research and Development, Biotech and Pharma, AI Drug Discovery, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Sep 2025 | $26M | $104M | Blitzscaling Ventures · The General Partnership · Mosaic Ventures · Westbound Equity Partners | ↗ |
| SEEDOther financing | Jan 2025 | $25M | $98M | Greylock Partners · Reid Hoffman · General Catalyst | ↗ |
Growth signals
Latest recorded traffic for Manas AI is 17K monthly website visits, down 51.4% over the last three months. Manas AI's team grew 833.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
Greylock Partners
Reid Hoffman
General Catalyst
Blitzscaling Ventures
The General Partnership
Mosaic Ventures
Westbound Equity Partners
Wisdom Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Manas AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Manas AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.